Bone Therapeutics SA

Bone Therapeutics SA, based in Belgium, specializes in developing innovative cell therapies for bone diseases and joint disorders, aiming to address critical unmet medical needs in orthopedics. Founded in 2006 and headquartered in Gosselies, Belgium, Bone Therapeutics SA focuses on advanced therapies for bone repair and regeneration. The company has undergone strategic changes to enhance its research and development capabilities and has completed a total of 10 funding deals. Notably, on February 4, 2015, Bone Therapeutics raised EUR 32.

2 million through an ADD-ON funding round led by Catalent, Inc. , which marked a significant milestone in its growth trajectory. The CEO of the company is Stephanie Patris, who has a history of leadership in the biotechnology sector. Bone Therapeutics SA develops cell-based therapies aimed at treating various bone and joint conditions.

Their primary focus is on advanced therapies that utilize stem cells and other innovative technologies to promote bone healing and regeneration. These products are designed to address significant medical needs in orthopedic treatments, providing new solutions for patients suffering from debilitating bone-related issues. In the most recent financial year, 2022, Bone Therapeutics SA reported zero revenue with an EBITDA of EUR -68,337. 3.

The company's future growth strategy includes the development and potential launch of new product lines focused on regenerative medicine for orthopedic applications. Bone Therapeutics is also looking to expand its market reach into Europe and North America by 2025, targeting regions with a high demand for innovative orthopedic treatments. The proceeds from the latest funding round of EUR 12. 00 mn will be strategically utilized to support these initiatives, including enhancing research capabilities and accelerating clinical trials.